

WHAT IS CLAIMED IS:

1. A method of modulating the trafficking of systemic memory T cells in a mammalian host, the method comprising:
 - 5 administering an effective amount of a CCR4 modulating agent, in a dose effective to modulate said trafficking of systemic memory T cells.
 2. The method of Claim 1, wherein said administration provides for a prolonged localized concentration of said CCR4 modulating agent.
 - 10 3. The method of Claim 2, wherein said systemic memory T cells are CD4⁺.
 4. The method according to Claim 2, wherein said memory T cells are CD8⁺.
 - 15 5. The method according to Claim 3, wherein said systemic memory T cells are CD45Ra⁻, and integrin $\alpha 4\beta 7$.
 6. The method of Claim 5, wherein said systemic memory T are further characterized as CLA⁺.
 - 20 7. The method of Claim 6, wherein said localized concentration of said CCR4 modulating agent is cutaneous.
 8. The method of Claim 1, wherein said CCR4 modulating agent is a CCR4 agonist.
 - 25 9. The method of Claim 8, wherein said CCR4 agonist is selected from the group consisting of TARC and MDC.

- 5

10. The method of Claim 1, wherein said CCR4 modulating agent is a CCR4 antagonist.

11. The method of Claim 10, wherein said CCR4 antagonist is an antibody.

12. The method of Claim 11, wherein said antibody is a monoclonal antibody.

13. A method of modulating the trafficking of CCR4+ skin homing leukocytes to cutaneous tissue or skin, the method comprising:
10 administering an effective amount of a CCR4 modulating agent, wherein said agent modulates the interaction between CCR4 and a ligand.

14. The method according to Claim 13, wherein said leukocyte is a lymphocyte.

15. The method according to Claim 14, wherein said lymphocyte is a T cell.

16. The method according to Claim 15, wherein said T cell is further characterized as CD4⁺.

20

17. The method according to Claim 16, wherein said T cell is further characterized as CD45Ra⁻, and integrin α4β7⁻.

25

18. A method of treating inflammatory skin disease, the method comprising:
administering to a patient an effective amount of a CCR4 antagonist, wherein
said CCR4 antagonist interferes with the interaction between CCR4 and a ligand.

19. The method according to Claim 18, wherein said CCR4 ligand is TARC or
MDC.
20. The method according to Claim 18, wherein said CCR4 antagonist is an
5 antibody.
21. The method according to Claim 20, wherein said antibody binds to CCR4.
22. The method according to Claim 20, wherein said antibody binds to a CCR4
10 ligand.

A handwritten signature consisting of stylized initials and a surname, written in black ink.